Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system.

As immuno-oncology companies look to extend the efficacy of marketed checkpoint inhibitors by pairing them with other immunotherapies, they generally pick a combination partner that either removes a second brake from the immune system, for example by blocking another checkpoint protein, or that directly activates immune cells, by amplifying proinflammatory signaling. ...